[{"orgOrder":0,"company":"Eisai","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Lenvatinib Mesylate","moa":"||VEGF receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Eisai \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Inapplicable"},{"orgOrder":0,"company":"Aragen Life Sciences","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"INDIA","productType":"Antibody","year":"2021","type":"Agreement","leadProduct":"Everolimus","moa":"||IGF-1 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Aragen Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aragen Life Sciences \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"8","companyTruncated":"Aragen Life Sciences \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Breckenridge Pharmaceutical","sponsor":"Natco Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Everolimus","moa":"kinase","graph1":"Oncology","graph2":"Approved FDF","graph3":"Breckenridge Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Breckenridge Pharmaceutical \/ Natco Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Breckenridge Pharmaceutical \/ Natco Pharma"},{"orgOrder":0,"company":"Biocon","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Everolimus","moa":"kinase","graph1":"Oncology","graph2":"Phase II","graph3":"Biocon","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Biocon \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Biocon \/ Inapplicable"},{"orgOrder":0,"company":"Eisai","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Lenvatinib","moa":"||VEGF receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Eisai \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Eisai \/ Inapplicable"},{"orgOrder":0,"company":"Breckenridge Pharmaceutical","sponsor":"Natco Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Everolimus","moa":"kinase","graph1":"Oncology","graph2":"Approved FDF","graph3":"Breckenridge Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Breckenridge Pharmaceutical \/ Natco Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Breckenridge Pharmaceutical \/ Natco Pharma"},{"orgOrder":0,"company":"Abbott Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Everolimus","moa":"kinase","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Abbott Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Abbott Laboratories \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Abbott Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"Abbott Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Everolimus","moa":"kinase","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Abbott Laboratories","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Abbott Laboratories \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Abbott Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"Breckenridge Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Everolimus","moa":"kinase","graph1":"Immunology","graph2":"Approved FDF","graph3":"Breckenridge Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Breckenridge Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Breckenridge Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Biocon Biologics","sponsor":"Eris Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Divestment","leadProduct":"Everolimus","moa":"kinase","graph1":"Oncology","graph2":"Approved FDF","graph3":"Biocon Biologics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Biocon Biologics \/ Eris Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Biocon Biologics \/ Eris Pharmaceuticals"},{"orgOrder":0,"company":"Isotope Technologies Munich","sponsor":"Temasek Life Sciences Laboratory","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Radiolabelled Compounds","year":"2023","type":"Financing","leadProduct":"177-Lu Edotreotide","moa":"||SST2 receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Isotope Technologies Munich","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Isotope Technologies Munich \/ Temasek Life Sciences Laboratory","highestDevelopmentStatusID":"10","companyTruncated":"Isotope Technologies Munich \/ Temasek Life Sciences Laboratory"},{"orgOrder":0,"company":"Breckenridge Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Everolimus","moa":"kinase","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Breckenridge Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Tablet, Orally Disintegrating","sponsorNew":"Breckenridge Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Breckenridge Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Upsher-Smith Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Everolimus","moa":"kinase","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Upsher-Smith Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Upsher-Smith Laboratories \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Upsher-Smith Laboratories \/ Inapplicable"}]

Find Clinical Drug Pipeline Developments & Deals for Zortress

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Details : Afinitor Disperz (everolimus) is an mTOR inhibitor small molecule drug candidate, which is currently being evaluated for the treatment of tuberous sclerosis complex.

                          Product Name : Afinitor Disperz-Generic

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          January 29, 2025

                          Lead Product(s) : Everolimus

                          Therapeutic Area : Rare Diseases and Disorders

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Breckenridge Pharmaceutical

                          02

                          Details : Breckenridge plans to launch Everolimus Tablets in 2.5mg, 5mg and 7.5mg strengths during the second quarter of 2021 in a blister card packaging configuration.

                          Product Name : Afinitor-Generic

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          August 03, 2021

                          Lead Product(s) : Everolimus

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved FDF

                          Sponsor : Natco Pharma

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Breckenridge Pharmaceutical

                          03

                          Details : Everolimus is the generic name for the trade name drug Afinitor. Breckenridge has launched 10mg strength of Everolimus Tablets used as an immunosuppressant to prevent rejection of organ transplants and in the treatment of renal cell cancer and other tumo...

                          Product Name : Afinitor-Generic

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          January 10, 2021

                          Lead Product(s) : Everolimus

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved FDF

                          Sponsor : Natco Pharma

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Breckenridge Pharmaceutical

                          04

                          Details : Zortress-Generic (everolimus) inhibits antigenic and interleukin (IL-2 and IL-15) stimulated activation and proliferation of T and B lymphocytes. It is indicated for the prophylaxis of organ rejection in adult patients.

                          Product Name : Zortress-Generic

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          January 06, 2021

                          Lead Product(s) : Everolimus

                          Therapeutic Area : Immunology

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Breckenridge Pharmaceutical

                          05

                          MAGHREB PHARMA
                          Not Confirmed
                          MAGHREB PHARMA
                          Not Confirmed

                          Details : Torpenz (everolimus) inhibits antigenic and interleukin (IL-2/15) stimulated activation and proliferation of T and B lymphocytes. It is indicated for Tuberous Sclerosis Complex.

                          Product Name : Torpenz

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          May 08, 2024

                          Lead Product(s) : Everolimus

                          Therapeutic Area : Rare Diseases and Disorders

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          MAGHREB PHARMA
                          Not Confirmed
                          MAGHREB PHARMA
                          Not Confirmed

                          Details : The FDA approved the Esprit™ BTK Everolimus Eluting Resorbable Scaffold System to keep arteries open, delivering Everolimus to support healing in patients with chronic limb-threatening ischemia.

                          Product Name : Esprit

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          April 29, 2024

                          Lead Product(s) : Everolimus

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          MAGHREB PHARMA
                          Not Confirmed
                          MAGHREB PHARMA
                          Not Confirmed

                          Details : Through the divestment, Eris gains Biocon's Dermatology and Nephrology branded formulations business units in India that mostly comprised of its legacy small molecules’ brands, including Advacan (everolimus), an anti-cancer medicine.

                          Product Name : Advacan

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          September 11, 2023

                          Lead Product(s) : Everolimus

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved FDF

                          Sponsor : Eris Pharmaceuticals

                          Deal Size : $43.8 million

                          Deal Type : Divestment

                          blank

                          08

                          MAGHREB PHARMA
                          Not Confirmed
                          MAGHREB PHARMA
                          Not Confirmed

                          Details : The net financing will support the development of ITM’s broad Targeted Radionuclide Therapies oncology pipeline and enhance phase III clinical development for its lead pipeline candidate, ITM-11 (n.c.a. 177Lu-edotreotide) in gastroenteropancreatic neur...

                          Product Name : ITM-11

                          Product Type : Radiolabelled Compounds

                          Upfront Cash : Undisclosed

                          May 06, 2023

                          Lead Product(s) : 177-Lu Edotreotide,Everolimus,Lysine

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Sponsor : Temasek Life Sciences Laboratory

                          Deal Size : $272.7 million

                          Deal Type : Financing

                          blank

                          09

                          MAGHREB PHARMA
                          Not Confirmed
                          MAGHREB PHARMA
                          Not Confirmed

                          Details : Xentuzumab* (BI 836845) is a humanized immunoglobulin G (IgG) 1 monoclonal antibody (mAb) that targets insulin-like growth factor (IGF) ligands IGF-1 and IGF-2 for treatment of breast cancer.

                          Product Name : BI 836845

                          Product Type : Antibody

                          Upfront Cash : Undisclosed

                          June 29, 2021

                          Lead Product(s) : Xentuzumab,Everolimus,Exemestane

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Boehringer Ingelheim GmbH

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          10

                          MAGHREB PHARMA
                          Not Confirmed
                          MAGHREB PHARMA
                          Not Confirmed

                          Details : Everolimus tablets, a generic version of Afinitor® have been introduced in four strengths of 2.5mg, 5mg, 7.5mg and 10mg, with the 10 mg tablet used to treat certain types of cancers and tumours.

                          Product Name : Afinitor-Generic

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          April 10, 2021

                          Lead Product(s) : Everolimus

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank